ACCUSTEM SCIENCES, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — |
| Operating Expenses | ||||||
| Research & Development | — | $281.0K | $138.3K | $139.7K | $266.9K | $73.3K |
| SG&A Expense | — | $1.5M | $1.4M | $1.9M | $3.5M | $597.3K |
| Operating Income | — | $-1.8M | $-1.5M | $-2.1M | $-3.7M | $-670.6K |
| Operating Margin | — | — | — | — | — | — |
| Interest Expense | — | — | — | — | — | — |
| Pretax Income | — | $-1.8M | $-1.5M | $-2.1M | $-3.7M | $-670.6K |
| Income Tax Expense | — | — | — | — | — | — |
| Net Income | — | $-1.8M | $-1.5M | $-2.1M | $-3.7M | $-670.6K |
| Net Margin | — | — | — | — | — | — |
| EPS (Basic) | — | $-0.12 | $-0.13 | $-0.18 | $-0.34 | $-0.07 |
| EPS (Diluted) | — | $-0.12 | $-0.13 | $-0.18 | $-0.34 | — |
| Shares Outstanding (Basic) | 16.1M | 15.2M | 11.4M | 11.3M | 11.0M | 10.0M |
| Shares Outstanding (Diluted) | 16.1M | 15.2M | 11.4M | 11.3M | 11.0M | 10.0M |
| Dividends Per Share | — | — | — | — | — | — |